Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Neutral

Analyst Rating

Neutral

Simple Moving Average

Sell

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Leap Therapeutics, Inc. Common Stock (LPTX)

Pharmaceutical Preparations

https://www.leaptx.com

Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P204,and P205.

47 THORNDIKE STREET, SUITE B1-1
CAMBRIDGE, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/31/2014

Market Cap

92,791,413

Shares Outstanding

25,570,000

Weighted SO

25,565,414

Total Employees

N/A

Upcoming Earnings

08/12/2024

Similar Tickers

XFOR --.--%

TERN --.--%

DAWN --.--%

PDSB --.--%

INZY --.--%

EFTR --.--%

ELEV --.--%

MREO --.--%

HEPA --.--%

Beta

0.3160

Last Div

0.0000

Range

1.235-5.0

Chg

-0.0350

Avg Vol

139183

Mkt Cap

92791413

Exch

NASDAQ

Country

US

Phone

617 714 0360

DCF Diff

-0.9924

DCF

3.4424

Div Yield

0.0000

P/S

146.3587

EV Multiple

-0.2255

P/FV

1.4421

Div Yield %

0.0000

P/E

-1.5783

PEG

-0.0906

Payout

0.0000

Current Ratio

5.1021

Quick Ratio

5.1021

Cash Ratio

5.0310

DSO

434.0852

DIO

0.0000

Op Cycle

434.0852

DPO

12839.1216

CCC

-12405.0364

Gross Margin

0.6498

Op Margin

-103.6751

Pretax Margin

-94.8091

Net Margin

-94.8091

Eff Tax Rate

-0.0143

ROA

-0.7382

ROE

-0.9801

ROCE

-0.9985

NI/EBT

1.0000

EBT/EBIT

0.9145

EBIT/Rev

-103.6751

Debt Ratio

0.0059

D/E

0.0073

LT Debt/Cap

0.0006

Total Debt/Cap

0.0073

Int Coverage

-76.1645

CF/Debt

-103.8485

Equity Multi

1.2377

Rec Turnover

0.8408

Pay Turnover

0.0284

Inv Turnover

0.0000

FA Turnover

1.3347

Asset Turnover

0.0078

OCF/Share

-1.2794

FCF/Share

-1.2794

Cash/Share

2.0060

OCF/Sales

-78.9511

FCF/OCF

1.0000

CF Coverage

-103.8485

ST Coverage

-112.9910

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

1.4421

P/B

1.4421

P/S

146.3587

P/E

-1.5783

P/FCF

-1.8538

P/OCF

-1.8954

P/CF

-1.8954

PEG

-0.0906

P/S

146.3587

EV Multiple

-0.2255

P/FV

1.4421

DPS

0.0000

Latest Headlines (EST)

Benzinga Nov 14, 12:00 Raymond James Maintains Outperform Rating for Leap Therapeutics: Here's What You Need To Know

Revenue Product Segmentation